Cover Image

Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy

Show other versions (1)

Despite introduction of effective chemotherapy protocols, it has remained uncertain, if patients with colorectal cancer (CRC) liver metastases should receive adjuvant therapy. Clinical or molecular predictors may help to select patients at high risk for disease recurrence and death who obtain a surv...

Full description

Saved in:
Bibliographic Details
Main Authors: Rahbari, Nuh Nabi (Author) , Reißfelder, Christoph (Author) , Schulze-Bergkamen, Henning (Author) , Jäger, Dirk (Author) , Büchler, Markus W. (Author) , Weitz, Jürgen (Author) , Koch, Moritz (Author)
Format: Article (Journal)
Language:English
Published: 11 March 2014
In: BMC cancer
Year: 2014, Volume: 14
ISSN:1471-2407
DOI:10.1186/1471-2407-14-174
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-14-174
Get full text
Author Notes:Nuh N. Rahbari, Christoph Reissfelder, Henning Schulze-Bergkamen, Dirk Jäger, Markus W. Büchler, Jürgen Weitz and Moritz Koch
Description
Summary:Despite introduction of effective chemotherapy protocols, it has remained uncertain, if patients with colorectal cancer (CRC) liver metastases should receive adjuvant therapy. Clinical or molecular predictors may help to select patients at high risk for disease recurrence and death who obtain a survival advantage by adjuvant chemotherapy.
Item Description:Gesehen am 05.08.2020
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-14-174

Similar Items